Hepatitis C News and Research

Latest Hepatitis C News and Research

World Hepatitis Alliance calls for comprehensive hepatitis strategies to help prevent liver cancer deaths

Rock-icon David Bowie died recently at the age of 69 after a battle with what is being reported as liver cancer. Each year, more than 800,000 people die from liver cancer globally, the second biggest cancer killer. Yet, a high majority of these deaths are completely preventable.

5 Feb 2016

UC Davis researchers develop Hepatitis virus-like particles to target breast cancer

UC Davis researchers have developed a way to use the empty shell of a Hepatitis E virus to carry vaccines or drugs into the body. The technique has been tested in rodents as a way to target breast cancer, and is available for commercial licensing through UC Davis Office of Research.

4 Feb 2016

Drinking extra 2 cups of coffee per day may reduce cirrhosis risk by 44%

Regular consumption of coffee was linked with a reduced risk of liver cirrhosis in a review of relevant studies published before July 2015.

1 Feb 2016

EC approves expanded use of Daklinza (daclatasvir) for patients with chronic HCV and HIV co-infection

Bristol-Myers Squibb today announced that the European Commission has approved the expanded use of Daklinza, a first-in-class oral, once-a-day pill used in combination with other treatments as an option for adult patients with chronic hepatitis C virus infection who are co-infected with HIV or who have had a prior liver transplant.

30 Jan 2016

NJHA honors several individuals and organizations with Healthcare Leader Awards

The New Jersey Hospital Association, the state's oldest and largest healthcare trade association, today held its annual awards program to honor several individuals and organizations for their commitment to the state's healthcare system and the patients and communities they serve.

30 Jan 2016

Zepatier receives FDA approval for treatment of chronic HCV genotypes 1 and 4 infections

The U.S. Food and Drug Administration today approved Zepatier (elbasvir and grazoprevir) with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) genotypes 1 and 4 infections in adult patients.

29 Jan 2016

FDA expands use of Opdivo + Yervoy Regimen for BRAF V600 mutant and wild-type advanced melanoma

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved Opdivo in combination with Yervoy for the treatment of patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma.

27 Jan 2016

Monitoring HBcrAg levels could help optimise PEG-IFN therapy

Serum hepatitis B core-related antigen could serve as a quantitative marker of response to pegylated interferon therapy in patients with chronic hepatitis B virus infection positive for hepatitis B e antigen (HBeAg), findings indicate.

26 Jan 2016

Rescue TDF monotherapy effective in multidrug resistant chronic HBV

Researchers from the Republic of Korea say that rescue therapy with tenofovir disoproxil fumarate alone is an appropriate option for patients with multidrug resistant chronic hepatitis B virus infection.

26 Jan 2016

STAT4 variant predicts HBV IFNα response

Variation in the STAT4 gene is associated with response to interferon (IFN)α therapy in patients with hepatitis B e antigen-positive chronic hepatitis B virus infection, suggests research published in Hepatology.

26 Jan 2016

Only 17.4% of nurses comply with all nine standard precautions for infection prevention

Only 17.4 percent of ambulatory care nurses reported compliance in all nine standard precautions for infection prevention, according to a study published in the January issue of the American Journal of Infection Control, the official publication of the Association for Professionals in Infection Control and Epidemiology.

21 Jan 2016

Study outlines new model to help predict age-related response to hepatitis B vaccine

Physicians have known for years that patients respond differently to vaccines as they age. There may soon be a new way to predict and enhance the effectiveness of vaccinations, in particular the hepatitis B vaccine.

20 Jan 2016

Scientists reveal why non-alcoholic steatohepatitis worsens in obese people

In results published on October 19, 2015 in the Journal of Lipid Research, a team of translational scientists at the Medical University of South Carolina report a new reason why non-alcoholic steatohepatitis (NASH) worsens in people who are obese.

20 Jan 2016

Estrogen helps women fight flu virus better than men

Estrogen dramatically reduced the amount of flu virus that replicated in infected cells from women but not from men, a new study by researchers at the Johns Hopkins Bloomberg School of Public Health shows.

20 Jan 2016

Estrogen may protect women against flu

The female sex hormone estrogen has anti-viral effects against the influenza A virus, commonly known as the flu, a new study in American Journal of Physiology—Lung Cellular and Molecular Physiology reports.

13 Jan 2016

Inflammation associated with elevated glutamate in the brain could guide depression treatments

Psychiatrists investigating depression have been energized in recent years by reports of rapid, successful treatment with drugs that interfere with the brain chemical glutamate, such as the anesthetic ketamine.

13 Jan 2016

Pre-existing nutritional deficits, immune dysfunction may increase hepatitis E risk during pregnancy

Researchers from the Johns Hopkins Bloomberg School of Public Health have found a link between pre-existing nutritional deficits and immune dysfunction and the risk of hepatitis E infection during pregnancy.

12 Jan 2016

AbbVie begins six global Phase 3 clinical studies to evaluate efficacy of investigational HCV regimen

AbbVie, a global biopharmaceutical company, today announced the initiation of six global Phase 3 clinical studies evaluating the safety and efficacy of its all-oral, once-daily, ribavirin-free investigational hepatitis C virus (HCV) regimen, ABT-493, an NS3/4A protease inhibitor, and ABT-530, an NS5A inhibitor, in patients with genotypes 1-6 (GT1-6) chronic HCV infection.

12 Jan 2016

GPR119 could be a potential treatment target for nonalcoholic fatty liver disease

New research published in the January 2016 issue of The FASEB Journal suggests that the G-protein-coupled receptor 119 (GPR119) could be a viable treatment target for nonalcoholic fatty liver disease. This receptor has already been identified as a drug target for diabetes and obesity, and this report raises hopes that compounds that target GPR119 for diabetes or obesity might also work for non-alcoholic fatty liver disease.

12 Jan 2016

ISHLT issues new list of criteria to determine patient eligibility for heart transplant

To determine patient eligibility for heart transplant, the International Society for Heart Lung Transplantation maintains a list of criteria, first issued in 2006, that acts as a guideline for physicians.

7 Jan 2016

Hepatitis C News and Research

Latest Hepatitis C News and Research

World Hepatitis Alliance calls for comprehensive hepatitis strategies to help prevent liver cancer deaths

UC Davis researchers develop Hepatitis virus-like particles to target breast cancer

Drinking extra 2 cups of coffee per day may reduce cirrhosis risk by 44%

EC approves expanded use of Daklinza (daclatasvir) for patients with chronic HCV and HIV co-infection

NJHA honors several individuals and organizations with Healthcare Leader Awards

Zepatier receives FDA approval for treatment of chronic HCV genotypes 1 and 4 infections

FDA expands use of Opdivo + Yervoy Regimen for BRAF V600 mutant and wild-type advanced melanoma

Monitoring HBcrAg levels could help optimise PEG-IFN therapy

Rescue TDF monotherapy effective in multidrug resistant chronic HBV

STAT4 variant predicts HBV IFNα response

Only 17.4% of nurses comply with all nine standard precautions for infection prevention

Study outlines new model to help predict age-related response to hepatitis B vaccine

Scientists reveal why non-alcoholic steatohepatitis worsens in obese people

Estrogen helps women fight flu virus better than men

Estrogen may protect women against flu

Inflammation associated with elevated glutamate in the brain could guide depression treatments

Pre-existing nutritional deficits, immune dysfunction may increase hepatitis E risk during pregnancy

AbbVie begins six global Phase 3 clinical studies to evaluate efficacy of investigational HCV regimen

GPR119 could be a potential treatment target for nonalcoholic fatty liver disease

ISHLT issues new list of criteria to determine patient eligibility for heart transplant

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Hepatitis C News and Research

Latest Hepatitis C News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in